Bupropion

Generic Name: Bupropion

Brand Names: Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈ClNO

CAS Number: 34911-55-2

Unique Ingredient Identifier: 01ZG3TPX31

Background: Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication: Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)

Associated Therapies: Smoking, Cessation, Weight Loss

Clinical Trials

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

Phase 3

Conditions: Tobacco Use
Nicotine Dependence

Interventions: Drug: Nicotine replacement therapy - Transdermal nicotine patch
Drug: Nicotine replacement therapy - Nicotine gum
Drug: Nicotine replacement therapy - Nicotine lozenge
Drug: Bupropion
Drug: Varenicline
Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum
Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge
Drug: Combination pharmacotherapy - Transdermal nicotine patch + bupropion
Behavioral: Tailored behavioral intervention
Behavioral: Tobacco quitline referral
Behavioral: Alcohol use risk reduction
Behavioral: Behavioral activation for depressive symptoms
Behavioral: Behavioral management of postcessation weight gain

First Posted Date: 2013-07-04

Last Posted Date: 2017-07-11

Lead Sponsor: Mark Vander Weg

Target Recruit Count: 411

Registration Number: NCT01892813

Locations: 🇺🇸
Iowa City VA Healthcare System, Iowa City, Iowa, United States

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Phase 2

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Chantix
Drug: Zyban
Drug: Nicotine patches

First Posted Date: 2013-03-07

Last Posted Date: 2016-01-18

Lead Sponsor: Duke University

Target Recruit Count: 376

Registration Number: NCT01806779

Locations: 🇺🇸
Duke Center for Smoking Cessation, Winston-Salem, North Carolina, United States

Contingency Management for Smoking Cessation in Homeless Smokers

Not Applicable

Completed

Conditions: Smoking
Homeless Persons

Interventions: Drug: Bupropion
Drug: Nicotine replacement therapy
Behavioral: Contingency Management

First Posted Date: 2013-02-12

Last Posted Date: 2015-06-12

Lead Sponsor: Duke University

Target Recruit Count: 25

Registration Number: NCT01789710

Locations: 🇺🇸
VA Medical Center, Durham, North Carolina, United States

Influence of Bupropion on the Effects of MDMA

Phase 1

Completed

Conditions: Healthy
Substance-related Disorders

Interventions: Drug: MDMA
Drug: Bupropion
Drug: Placebo

First Posted Date: 2013-01-18

Last Posted Date: 2016-01-21

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 16

Registration Number: NCT01771874

Locations: 🇨🇭
University Hospital Basel, Basel, Basel-Stadt, Switzerland

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: LDE225
Drug: Wafarin
Drug: Bupropion

First Posted Date: 2013-01-17

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 114

Registration Number: NCT01769768

Locations: 🇺🇸
Massachusetts General Hospital Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr, Lebanon, New Hampshire, United States

and more 10 locations